Hyperthermic intraperitoneal chemotherapy (HIPEC) provides an important treatment option that can improve survival for some patients with advanced peritoneal cancer. Managing this disease — and ...
Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) origin is associated with poor outcome. This systematic review evaluates the available evidence about adjuvant (hyperthermic) intraperitoneal ...
Cancers originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and liver) account for approximately 250,000 new cancer cases annually in the USA. Peritoneal ...
In patients with tumors confined to the peritoneal cavity, there is established pharmacokinetic and tumor biology-related evidence that intraperitoneal drug administration is advantageous. Three large ...
EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 67-year-old man in relatively good health presented to ...
Please provide your email address to receive an email when new articles are posted on . The addition of intraperitoneal paclitaxel to systemic capecitabine and oxaliplatin appeared to benefit patients ...
Another major limitation of IP therapy is the lack of efficacy in larger, bulky tumors. In ovarian cancer, the postsurgical residual tumor size is the most significant prognostic indicator for IP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results